News Quantified

JAZZ – jazz pharmaceuticals plc - ordinary shares (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Jazz Pharmaceuticals plc (JAZZ) Jumps Nearly 30% on Strong Q3 and Cancer Drug Trial Progress [Yahoo! Finance]

Jazz Pharmaceuticals (JAZZ) is now covered by Barclays PLC. They set an "overweight" rating and a $224.00 price target on the stock.

A Look At Jazz Pharmaceuticals (JAZZ) Valuation After Record Quarter And 2026 Guidance [Yahoo! Finance]

Jazz Pharmaceuticals plc Q4 2025 Earnings Call Summary [Yahoo! Finance]

Jazz Pharmaceuticals (JAZZ) Stock Trades Up, Here Is Why [Yahoo! Finance]

13.2%

BEAT

-2.3%

BEAT

-6.4%

MISS

-3.4%

MISS

Form 144 Jazz Pharmaceuticals Filed by: Carr Patricia

Form 144 Jazz Pharmaceuticals Filed by: RIEDEL NORBERT G

Form 144 Jazz Pharmaceuticals Filed by: Patil Neena M

Form 144 Jazz Pharmaceuticals Filed by: Carr Patricia

Form 144 Jazz Pharmaceuticals Filed by: Henderson Mary Elizabeth

Top News Gainers

5/7 Q1/2019 3/31/2019 EPS 3.670 ZacksConsensus 2.830 ActVsEst 0.840 - Beat 9.3%

4/6 Jefferies sees 51% upside in Jazz Pharma in premarket analyst action [Seeking Alpha] 7.1%

9/10 Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) was downgraded by analysts at ValuEngine from a "sell" rating to a "strong sell" rating. 5.0%

11/14 Jazz Pharmaceuticals Announces Participation at Upcoming Investor Conferences 3.7%

11/7 Form 3 Jazz Pharmaceuticals For: Oct 31 Filed by: Larkin Finbar 3.3%

1/14 Form 8-K Jazz Pharmaceuticals For: Jan 13 3.0%

4/24 Form 10-K/A Jazz Pharmaceuticals For: Dec 31 2.8%

12/19 PharmaMar and Jazz Pharmaceuticals Sign Exclusive License Agreement for Lurbinectedin in the U.S. 2.6%

11/22 Edited Transcript of JAZZ earnings conference call or presentation 5-Nov-19 9:30pm GMT [Yahoo! Finance News] 2.6%

4/28 Can This Small-Cap Biotech Win a $1 Billion Market Opportunity for Narcolepsy? [The Motley Fool] 2.5%

Top News Decliners

3/13 Form 4 Jazz Pharmaceuticals For: Mar 12 Filed by: MILLER MICHAEL PATRICK -11.3%

2/25 Q4/2019 12/31/2019 EPS 4.420 ZacksConsensus 3.610 ActVsEst 0.810 - Beat -8.4%

3/3 Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -7.8%

6/17 Jazz Pharmaceuticals Receives Schedule IV Designation from DEA for Sunosi™ (solriamfetol) -7.1%

10/7 Form 8-K Jazz Pharmaceuticals For: Oct 03 -5.6%

8/6 Jazz Pharmaceuticals Announces Second Quarter 2019 Financial Results -4.8%

11/5 Jazz Pharmaceuticals EPS beats by $0.51, beats on revenue [Seeking Alpha] -4.3%

3/31 Jazz Pharmaceuticals Provides COVID-19 Business Update -4.1%

3/5 Form 4 Jazz Pharmaceuticals For: Mar 03 Filed by: Carr Patricia -3.8%

4/29 Jazz Pharmaceuticals Stops Enrollment in Phase 3 Study Evaluating Defibrotide for the Prevention of Veno-Occlusive Disease -3.6%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day